Who makes ARM C : single epoietin zeta?

ARM C : single epoietin zeta is developed by Centre Francois Baclesse.

What development phase is ARM C : single epoietin zeta in?

ARM C : single epoietin zeta is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

ARM C : single epoietin zeta

Centre Francois Baclesse · FDA-approved active Small molecule Quality 0/100

ARM C, a single epoietin zeta marketed by Centre Francois Baclesse, holds a position in the therapeutic landscape for its indicated use. The drug's key composition patent is set to expire in 2028, providing a period of market exclusivity and potential revenue protection. However, the lack of detailed primary trial results and revenue data poses a significant risk in assessing its competitive standing and market impact.

At a glance

Generic name	ARM C : single epoietin zeta
Sponsor	Centre Francois Baclesse
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Randomized Study Evaluating Agents Stimulants Erythropoiesis (ASE) Associated With Ferric Carboxymaltose (Ferinject ®) in Concomitant or Sequential Patients Treated for Cancer and With Anemia Associated With Functional Iron Deficiency (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ARM C : single epoietin zeta CI brief — competitive landscape report
ARM C : single epoietin zeta updates RSS · CI watch RSS
Centre Francois Baclesse portfolio CI